Last updated: 11/07/2018 00:46:25
An Open-Label, Multicenter, Non-Comparative Study of Topotecan as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) in Patients with Small Cell Lung Cancer
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An Open-Label, Multicenter, Non-Comparative Study of Topotecan as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) in Patients with Small Cell Lung Cancer
Trial description: An Open-Label, Multicenter, Non-Comparative Study of Topotecan as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) in Patients with Small Cell Lung Cancer
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Eckardt J, Gralla R, Palmer MC, et al: Topotecan (T) as Second-Line Therapy in Patients (Pts) with Small Cell Lung Cancer (SCLC): A, Phase II Study (abst). 21st Congress of ESMO, November 1996; Vol 7 (Suppl 5): 107.
New drugs in non-small cell lung cancer. Bunn, Paul A. Jr. MD 15th International Congress on Anti-Cancer Treatment 2/9/2004 Paris; France"
Topotecan as a single agent in second line therapy of small cell lung cancer (sclc). Huber, R M, Bultzingslowen, F V, Steppert, C, Gosse, H, Gatzemeier, U, and Pawel, J V 1999 Annual Congress of the European Respiratory Society 10/9/1999 Madrid; Spain
Medical condition
Lung Cancer, Small Cell
Product
topotecan
Collaborators
Not applicable
Study date(s)
June 1994 to July 1996
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1996-12-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website